| Jan 8, 2026 | Parabilis Medicines | $305.0M Series F | Jake Simson | Catalio Capital Management, Foresite Capital, ARCH Venture Partners, Cormorant Asset Management, Farallon Capital Management, Frazier Life Sciences, Freepoint Capital Group, General Catalyst, HBM Healthcare Investments, Invus, Marshall Wace, Milky Way Investments, Nextech Invest, Rock Springs Capital, Sixty Degree Capital, T. Rowe Price Associates |
| May 27, 2025 | Pillar Biosciences | $34.5M Other Equity | — | Ashley Van Zeeland, Benjamin Lund |
| Oct 31, 2024 | Blue Earth Therapeutics | $76.5M Series A | Sands Capital, Soleus Capital | — |
| May 1, 2024 | AltruBio | $230.0M Series B | Gorjan Hrustanovic | RA Capital, Third Rock Ventures, Alice Zhang, Evan Cheng, Blackstone, Cormorant Asset Management, Jake Simson |
| Dec 14, 2023 | Parse Biosciences | $50.0M Series C | David Canner | Bioeconomy Capital, Janus Henderson Investors, Marshall Wace, Sahsen Ventures, Saras Capital |
| Sep 1, 2023 | Star Therapeutics | $90.0M Series C | Sofinnova Investments | Foresite Capital, OrbiMed, Sanofi Ventures, Versant Ventures, Westlake Village BioPartners, Agent Capital, Catalio Capital Management, Cormorant Asset Management, Cowen Healthcare Investments, Vijay Lathi, NYBC Ventures, Qatar Investment Authority, Matthew Hammond, Amrit Nagpal |
| Aug 17, 2023 | COMPASS Pathways | $285.1M Other Equity | Aisling Capital, TCGX | Armistice Capital, Laurion Capital Management, Logos Capital, Paradigm BioCapital, PFM Health Sciences, RA Capital Management, Surveyor Capital, Vivo Capital |
| Sep 1, 2022 | RayzeBio | $160.0M Series D | Sofinnova Investments, Viking Global Investors, Irina Margine, Ph.D. | Cambridge Innovation Capital, Forbion, Ally Bridge Group, Laurion Capital Management, Sands Capital |
| Apr 1, 2022 | LimFlow SA | $39.0M Series D | — | Longitude Capital, Soffinova Partners, Balestier, Bpifrance |
| Feb 1, 2022 | Parse Biosciences | $42.0M Series B | Janus Henderson Investors, Marshall Wace | Bioeconomy Capital, Logos Capital |
| Dec 1, 2021 | Freenome | $300.0M Series D | Ellen Hukkelhoven, Peter Kolchinsky | Anzu Partners, Ameena El-Bibany, Vasudev Bailey, Artis Ventures (AV), Asset Management Ventures, Bain Capital Life Sciences, Cofounders Capital, Merck Global Health Innovation Fund, Polaris Partners, RA Capital, Section 32, Anne Wojcicki, Timothy A. Springer, Andreessen Horowitz, ArrowMark Partners, BrightEdge Ventures, Byers Capital, Catalio Capital Management, Data Collective, Eventide Asset Management, Farallon Capital Management, Fidelity Management & Research Company, Google Ventures, HBM Healthcare Investments, Intermountain Ventures, Janus Henderson Investors, Kaiser Permanente, Logos Capital, Novartis, Polaris Partners, Pura Vida Investments, Ridgeback Capital Investments, Thomas Schinecker, Rock Springs Capital, Sands Capital, Suvretta Capital Management, T. Rowe Price Associates |
| Nov 1, 2021 | Antios Therapeutics | $75.0M Series B | EPIQ Capital Group, Craig Gordon | Domain Associates, Pontifax Venture Capital, Adage Capital Management, Aisling Capital, Altium Capital, Amzak Health, Avego Bioscience Capital, CAM Capital, Delos Capital, Granite Point Capital, GRA Venture Fund, Heartland Healthcare Capital, LifeSci Venture Partners, Lumira Ventures, RA Capital Management, Sixty Degree Capital |
| Sep 1, 2021 | INBRACE | $100.0M Series D | Farallon Capital Management, Marshall Wace | KohFounders, Novo Ventures, Sofinnova Investments, venBio, Venrock, Versant Ventures, Vivo Capital, BlackRock, Rob Barmann, MVM Partners, RTW Investments |
| Sep 1, 2021 | Obsidian Therapeutics | $120.0M Series B | The Column Group | Atlas Venture, F-Prime Capital Partners, Amgen Ventures, Bristol Myers Squibb, Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, RA Capital Management, Samsara BioCapital, Surveyor Capital, Vertex, Vertex Ventures HC |
| Aug 1, 2021 | Dice Therapeutics | $60.0M Series C | RA Capital Management, Sands Capital | RA Capital, Samsara BioCapital, Versant Ventures, Asymmetry Capital Management, Deep Track Capital, Driehaus Capital Management, Eventide Asset Management, Janus Henderson Investors, Logos Capital, New Leaf Venture Partners, Northpond Ventures, Osage University Partners |
| Jul 27, 2021 | Artios | $152.0M Series C | Michelle Doig, Chen Yu | Andera Partners, Mark Chin, Avidity Partners, dRx Capital, Invus, LSP, M Ventures, Piper Heartland Healthcare Capital, RTW Investments, Schroders Capital, Sofinnova Partners, SV Health Investors, Tetragon Financial Group |
| Jul 1, 2021 | Artios Pharma | $150.0M Series C | Michelle Doig, Chen Yu | Andera Partners, EQT Life Sciences, Hakan Goker, M Ventures (Merck), Novartis Venture Fund, Pfizer Venture Investments, Arix Bioscience, Avidity Partners, CaaS Capital Management, Deep Track Capital, Invus, LSP, Novartis, Piper Heartland Healthcare Capital, RTW Investments, Schroders Capital, Sofinnova Partners, SV Health Investors, Tetragon Financial Group |
| May 27, 2021 | Genapsys | $70.0M Series D | — | Farallon Capital Management |
| May 1, 2021 | TwinStrand Biosciences | $50.0M Series B | Section 32 | BoxGroup, GSR Ventures, Lightspeed China Partners, Madrona Ventures, Mayfield, Mischief Venture Capital, Third Rock Ventures, Jon Gelsey, Scott Belsky, Alexandria Venture Investments, Janus Henderson Investors, Ridgeback Capital Investments |
| Apr 1, 2021 | Antios Therapeutics | $96.0M Series B | Guy Levy | Domain Associates, Michele Park, Pontifax Venture Capital, Sanofi Ventures, Adage Capital Management, Aisling Capital, Amzak Health, CAM Capital, Delos Capital, Granite Point Capital, LifeSci Venture Partners, Lumira Ventures, RA Capital Management, Sixty Degree Capital |
| Feb 12, 2021 | Q'Apel Medical | $22.0M Series C | — | Research Corporation Technologies |
| Feb 4, 2021 | Inivata | $35.1M Series C Extension | Guy Levy | Farallon Capital Management, Janus Henderson Investors |
| Jan 1, 2021 | Werewolf Therapeutics | $72.0M Series B | Derek DiRocco | RA Capital, Adage Capital Management, Arkin Bio Ventures, CaaS Capital Management, DC Investment Partners, Elise Wang, HBM Healthcare Investments, Longwood Fund, MPM Capital, Sphera Healthcare, Taiho Ventures, UPMC Enterprises |
| Jan 1, 2021 | Dice Therapeutics | $80.0M Series C | Jake Simson | RA Capital, Samsara BioCapital, Versant Ventures, Agent Capital, Alexandria Venture Investments, Altitude Life Science Ventures, Asymmetry Capital Management, Driehaus Capital Management, Eventide Asset Management, New Leaf Venture Partners, Northpond Ventures, Osage University Partners, Sands Capital, Sanofi Ventures |
| Dec 24, 2020 | SomaLogic | $81.0M Series A Extension | Eli Casdin | Amgen Ventures, Boston Millennia Partners, Farallon Capital Management, Fiscus Ventures, Foresite Capital, Intermountain Ventures, Janus Henderson Investors, Logos Capital, Madryn Asset Management, Monashee Investment Management, Mossrock Capital, NEC Solution Innovators, Novartis, Redmile Group, Reimagined Ventures, Revelation Partners, Roy Smythe, T. Rowe Price Associates, Ziff Capital Partners |
